Truist Maintains Buy on SNV - PT $56

David Smith— Truist SecuritiesSNVVisible Alpha

Received

4/9/2026, 7:10:25 PM

Published

9/24/2025, 12:00:00 AM

Summarized

4/9/2026, 7:10:25 PM

AI Summary

**Rating:** Buy (Maintained)\n**Price Target:** $56 (from $58)\n**Analyst:** David Smith, Truist Securities\n\nTruist remains bullish on Synovus despite a minor PT trim. Smith continues to see value in the franchise ahead of the Pinnacle combination.

Full Report Content (90 characters)

Truist analyst David Smith maintains Buy on Synovus, lowering PT slightly from $58 to $56.

Metadata

{
  "action": "maintains",
  "rating": "buy",
  "price_target": 56,
  "prev_price_target": 58
}